



## Samuel Hochstrasser

Associate, M.A. HSG in Law  
and Economics, Attorney-at-law, LL.M.

samuel.hochstrasser@nkf.ch  
D +41 58 800 84 43

Languages  
German, English, French

## Expertise

Samuel Hochstrasser is a member of the Transactions Team of Niederer Kraft Frey. His practice focuses on domestic and cross-border M&A, capital markets and private equity transactions. Additionally, his expertise includes corporate, commercial and contract law.

## Career

- Since 2017 Associate, Niederer Kraft Frey
- 2015 Clerk with the District Court of Aarau
- 2014 Junior Associate, Niederer Kraft Frey

## Education

- 2016 Admitted to the Bar (Rechtsanwalt)
- 2014 University of St. Gallen, Master of Arts HSG in Law and Economics
- 2011 University of St. Gallen, Bachelor of Arts HSG in Law and Economics

## Experience

Recent matters in which Mr. Hochstrasser acted on include:

- BioTelemetry, Inc. on its competing public tender offer to the shareholders of LifeWatch AG (2017)
- Knorr-Bremse AG, the world's leading manufacturer of braking systems for rail and commercial vehicles, in the acquisition of Selectron Systems AG, Lyss (2014/2015)
- Underwriters in the CHF 2.3 billion IPO of Sunrise Communications, Switzerland's second largest telecom operator, on SIX Swiss Exchange and the financing banks in the IPO-related refinancing transactions (largest Swiss IPO since 2006 and largest IPO of telecom operator in EMEA since 2004) (2015)

## NIEDERER KRAFT FREY

- Bridgepoint in connection with the sale of Infront Sports & Media AG to Dalian Wanda Group Co. Ltd. (2015)
- NJJ Capital SAS (Xavier Niel) in the acquisition of Orange Communications SA, Switzerland's third largest telecom operator, for a total transaction value of CHF 2.8 billion (2014)
- SIX listed Leonteq in connection with its fully underwritten CHF 173 million rights offering (2014)
- OC Oerlikon Corporation AG in the CHF 1 billion acquisition of Sulzer Metco (2014)
- GlaxoSmithKline plc on its asset swap (Vaccines, Oncology) and joint venture (Consumer Healthcare) transaction with Novartis (2014)
- Cantonal Bank of Thurgau on its CHF 160 million initial public offering and listing on SIX Swiss Exchange of participation certificates (2014)